Company intelligence / Profile preview

Phi Life Sciences

Charleston, South Carolina, United Statesphilifesciences.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Phi Life Sciences provides accredited molecular diagnostic laboratory services focused on early disease detection and precision medication management. The company offers COVID‑19 PCR/antigen testing, infectious disease screening, pharmacogenomics/cancer genomics panels, validation of new tests/devices for partners, and custom support for clinical trials. It was the first U.S. distributor of MDNA's liquid biopsy test for prostate cancer.

Therapeutic areas: OtherOncologyInfectious Diseases
Modalities: Molecular diagnostic testGenotyping and gene expression analysisNext-generation sequencing (NGS)Companion diagnosticsRT-PCR (for COVID testing)Small molecule
Industry: Molecular Diagnostics

Partnerships

MDNA Life Sciences

Beyond the preview

Go deeper on Phi Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phi Life Sciences.

Explore the full profile